Entrectinib
| CAS No. | 1108743-60-7 | Cat. No. | BCP16174 |
| Name | Entrectinib | ||
| Synonyms | RXDX101; RXDX 101; RXDX-101; NMS E628; NMS-E628;NMS E628; | ||
| Formula | C31H34F2N6O2 | M. Wt | 560.64 |
| Description | Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | Trk Receptor ALK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.